PRODUCT MONOGRAPHS
Reliéva Cream Product Monograph
Reliéva Lotion Product Monograph
MULTICENTRE TRIAL
In an open label prospective multicentre trial (89 dermatological practices in Germany) 433 patients with subacute and chronic forms of psoriasis were treated with Mahonia aquifolium. According to an overall evaluation by dermatologists, symptoms improved or disappeared in 81.1% of patients. According to patient evaluations, 79.7% improved or healed completely.
To see the complete study, open the attached pdf file.
RECENT CLINICAL TRIALS
Several open-label and placebo-controlled clinical trials have been performed to assess the efficacy and safety of Mahonia aquifolium. Wiesenauer et al (1992) demonstrated in a double-blind study that topical Mahonia aquifolium produced a statistically significant difference (P<0.05) in the patient’s assessment of disease severity. Gieler (1995) and Augustin (1996) demonstrated high rates of disease improvement and a low side effect profile. Results from these three open-label clinical trials are in agreement with published data that includes placebo-controlled studies.
Taken together, these clinical studies conducted by several investigators in several countries indicate that Mahonia aquifolium is a safe and effective treatment for patients with mild to moderate psoriasis.
To see a report on three recent clinical trials utilizing Mahonia aquifolium 10% topical cream and worldwide clinical experience with Mahonia aquifolium for the treatment of plaque psoriasis, open the attached pdf file.
NOVASOME® DELIVERY SYSTEM
Reliéva™ therapeutic cream and lotion
with Psorberine™ natural extract (Mahonia aquifolium 10%)
Mahonia aquifolium is a plant, rich in berberine alkaloid, well know for it’s antiproliferative, antioxidant and anti-inflammatory properties. Apollo Pharmaceutical researchers have refined the plant extraction process to yield Psorberine™… a highly concentrated active.
Psorberine™ is then encapsulated into a patented Novasome® (visit www.askigi.com) delivery system to:
IMPROVE PENETRATION
Each microvesicle is only 0.5-0.7 microns, and
- INCREASE BIOAVAILABILITY
Each microvesicle contains multiple compartments of Psorberine™ to provide a prolonged release of active ingredient.
PERFORMANCE SUMMARY
 |
An effective, low risk treatment for plaque psoriasis
- Effectiveness comparable to conventional treatments
- Natural (non-steroidal) active
- Exceptional safety profile
- Low incidence of side effects
- Cosmetically acceptable for everyday use
- Excellent patient compliance
|
